Precigen, Inc. is a dedicated discovery and clinical-stage biopharmaceutical company advancing gene and cell therapies. The Companyâ€™s proprietary technology platforms develops product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company operates through two segments: Biopharmaceuticals and Exemplar. Biopharmaceuticals segment is primarily comprised of the Company's legal entities of Precigen and ActoBio, as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. Exemplar segment is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar (Exemplar), its wholly owned subsidiary focused on developing research models and services for healthcare research applications.

Employees

143

Sector

Pharmaceuticals

Calendar

Mar. 25 - Earnings release - Annual 2025

More about the company

Quotes

Date	Price	Change	Volume
26-03-13	3.510 $	+7.01%	2,802,079
26-03-12	3.280 $	-4.09%	2,274,473
26-03-11	3.420 $	-2.56%	1,962,030
26-03-10	3.510 $	0.00%	2,338,438
26-03-09	3.510 $	+5.72%	2,560,129

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.510USD

Average target price

8.500USD

Spread / Average Target

+142.17%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-13 pm EDT			5-day change	1st Jan Change
3.510 ^USD	+7.01%		+5.72%	-16.03%

Jan. 20	Precigen, Inc. Announces the Publication for The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis	CI
Jan. 15	Precigen, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-15-2026 07:30 AM

Capitalization	1.24B 1.09B 981M 938M 1.71B 115B 1.77B 11.72B 4.64B 54.88B 4.66B 4.56B 198B	P/E ratio 2025 *	-4x	P/E ratio 2026 *	-19.5x
Enterprise value	1.23B 1.08B 974M 931M 1.69B 114B 1.76B 11.63B 4.61B 54.49B 4.63B 4.53B 197B	EV / Sales 2025 *	91.1x	EV / Sales 2026 *	12.6x
Free-Float	90.08%	Yield 2025 *	-	Yield 2026 *	-

Jan. 20	Precigen, Inc. Announces the Publication for The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis	CI
Jan. 15	Precigen, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-15-2026 07:30 AM
Jan. 12	Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-And-Only Fda-Approved Therapy for RRP	CI
Dec. 23	Precigen Insider Sold Shares Worth $7,942,150, According to a Recent SEC Filing	MT
Nov. 24	Precigen Insider Sold Shares Worth $12,291,748, According to a Recent SEC Filing	MT
Nov. 13	Precigen, Inc., Q3 2025 Earnings Call, Nov 13, 2025
Nov. 13	Precigen Q3 Loss Widens, Revenue Rises	MT
Nov. 13	Biopharmaceutical company Precigen Q3 net loss widens	RE
Nov. 13	Earnings Flash (PGEN) Precigen Posts Q3 Loss Per Share $1.06, vs. FactSet Est of $0.09 Loss, If Comparable	MT
Nov. 13	Earnings Flash (PGEN) Precigen, Inc. Reports Q3 Revenue $2.92M	MT
Nov. 13	Precigen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-13	Precigen, Inc. Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses After Treatment with Papzimeos	CI
25-10-13	Precigen Says Drug for Rare Respiratory Disease Shows Durable Outcomes	MT

25-08-15	HC Wainwright Adjusts Price Target on Precigen to $8.50 From $6, Maintains Buy Rating	MT
25-08-15	JPMorgan Upgrades Precigen to Neutral From Underweight	MT
24-06-03	Stifel Adjusts Precigen's Price Target to $10 From $7, Keeps Buy Rating	MT
24-03-22	Precigen Shares Fall After Downgrade From JPMorgan	MT
24-03-22	JPMorgan Downgrades Precigen to Underweight From Neutral	MT

Precigen, Inc. Stock

Equities

PGEN

US74017N1054

Pharmaceuticals

Valuation: Precigen, Inc.

Chart: Precigen, Inc.

Latest news: Precigen, Inc.

Last Transcript: Precigen, Inc.

Analysts' recommendations: Precigen, Inc.

Press Releases: Precigen, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Precigen, Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Mar. 11	Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25	PR
Jan. 20	New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis	PR
Jan. 12	Precigen : January 2026	PU
Jan. 12	Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference	PR
Jan. 05	Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference	PR

1 day	+7.01%
1 week	+5.72%
Current month	-7.39%
1 month	-28.80%
3 months	-4.88%
6 months	-7.39%
Current year	-16.03%

1 week	3.26	3.59
1 month	3.22	5.46
Current year	3.22	5.46
1 year	1.11	5.46
3 years	0.65	5.46
5 years	0.65	9.59
10 years	0.65	39.49

Manager	Title	Age	Since
Helen Sabzevari CEO	Chief Executive Officer	64	2019-12-31
Harry Thomasian DFI	Director of Finance/CFO	64	2021-09-30
Amy Lankford CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Randal Kirk CHM	Chairman	72	2008-01-31
Cesar Alvarez BRD	Director/Board Member	78	2008-01-31
Jeffrey Kindler BRD	Director/Board Member	70	2011-11-27

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
PRECIGEN, INC.	+7.01%	+5.72%	+95.00%	+219.09%	1.24B
ELI LILLY AND COMPANY	+0.80%	-0.53%	+21.09%	+201.18%	880B
JOHNSON & JOHNSON	-0.21%	+0.47%	+48.34%	+56.91%	582B
ABBVIE INC.	-2.52%	-4.53%	+3.74%	+42.79%	388B
ROCHE HOLDING AG	+0.79%	-6.01%	+4.87%	+20.81%	324B
ASTRAZENECA PLC	+0.11%	-0.83%	+19.89%	+34.57%	295B
NOVARTIS AG	+0.43%	-1.54%	+25.96%	+62.12%	293B
MERCK & CO., INC.	-0.26%	-0.16%	+22.25%	+8.08%	286B
AMGEN INC.	-0.43%	-0.90%	+16.74%	+58.82%	197B
GILEAD SCIENCES, INC.	+0.42%	+0.74%	+30.11%	+81.76%	180B
Average	+0.61%	-0.76%	+28.80%	+78.61%	342.74B
Weighted average by Cap.	-0.02%	-1.37%	+22.88%	+84.86%

	2025 *	2026 *
Net sales	13.53M 11.83M 10.68M 10.22M 18.59M 1.25B 19.33M 128M 50.58M 598M 50.77M 49.7M 2.16B	98.61M 86.19M 77.87M 74.49M 135M 9.12B 141M 930M 369M 4.36B 370M 362M 15.74B
Net income	-266M -232M -210M -201M -365M -24.57B -379M -2.51B -993M -11.74B -997M -976M -42.4B	-53.52M -46.78M -42.26M -40.43M -73.53M -4.95B -76.44M -505M -200M -2.36B -201M -197M -8.54B
Net Debt	-8.9M -7.78M -7.03M -6.72M -12.23M -823M -12.71M -83.96M -33.27M -393M -33.4M -32.69M -1.42B	-